ACADIA Pharmaceuticals (ACAD) investor relations material

Strategic and operational updates

• Leadership focused on stabilizing commercial business and identifying new growth opportunities, including significant changes to field force sizing and commercial strategy for key brands.

• Targeting nearly $1 billion in combined commercial brand revenue by 2028, supported by enhanced marketing and sales efforts.

• Maintains a strong balance sheet with $851 million and no debt, actively seeking late-stage and pre-clinical business development opportunities, especially in rare diseases.

• Commercial infrastructure being leveraged for expansion beyond current products, with a robust pipeline of phase II and III trials expected to yield results in the next few years.

Product performance and market strategy

• NUPLAZID's commercial opportunity was reassessed, leading to a 30% increase in field force and a focus on expanding prescriber base, aiming for $1 billion in sales by 2028.

• Direct-to-consumer campaigns, including a high-profile unbranded campaign, have quadrupled awareness of hallucinations and delusions, broadening prescriber types.

• Current market share for NUPLAZID is 20%-25%, with expectations for significant growth.

• Patent protection extends to 2030 (composition of matter) and 2038 (MoU), with anticipated IRA price reductions between 2029 and 2031, but a strong market runway remains.

DAYBUE launch and innovation

• DAYBUE launch adjustments included increasing field force and evolving patient support, resulting in stabilized persistency rates and improved physician outreach.

• Addressed GI side effects and improved patient experience with the introduction of DAYBUE STIX, a flexible powder formulation, leading to renewed interest from new, switch, and returning patients.

• Early uptake of DAYBUE STIX shows 70% switchers and 30% new or returning patients, with incremental patient growth tracking ahead of guidance.